Summit Therapeutics Q2 net loss narrows on lower stock compensation

Summit Therapeutics

23/07/2026 21:19

    

    Overview
  
US oncology drug developer's Q2 net loss narrowed yr/yr on lower stock-based compensation
Non-GAAP net loss widened as clinical trial and development costs increased
Company ended Q2 with $690.7 mln in cash and investments after raising funds via ATM facility

    

    Outlook
  
Summit expects FDA decision on ivonescimab BLA by Nov. 14, 2026
Company anticipates HARMONi-3 squamous cohort PFS events in H2 2026, non-squamous in H1 2027
Summit plans further expansion of global Phase III ivonescimab studies in additional tumor types

    

    Result Drivers
  
HIGHER CLINICAL TRIAL SPENDING - Non-GAAP operating expenses rose due to expansion of clinical studies and development costs related to ivonescimab
LOWER STOCK-BASED COMPENSATION - GAAP operating expenses and net loss fell yr/yr due to a decrease in stock-based compensation expense after modification of performance-based stock option awards
INFRASTRUCTURE EXPANSION - Non-GAAP G&A expenses increased due to expansion of infrastructure and headcount to support ivonescimab development

    
Company press release: ID:nBw5C2Tj1a

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Loss Per Share
 
$0.28
 
Q2 Net Loss
 
$215.70 mln
 
Q2 Operating Expenses
 
$220.50 mln
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 5 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Summit Therapeutics Inc is $33.00, about 123.9% above its July 22 closing price of $14.74

    

    Reuters Recommended Reads
  
July 22 - Pfizer's prostate cancer drug combination gets US FDA priority review
July 22 - GSK enters lung cancer drug market with early FDA nod for Jideytro
July 22 - Community Health Q2 revenue falls more than expected, hurt by sale of hospitals

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)